tafamidis
Wed, 22 Dec 2021 14:30:43 -0500
Vyndaqel is indicated for the treatment of adult patients with cardiomyopathy due to transthyretin-mediated amyloidosis, wild-type or hereditary, to reduce cardiovascular mortality and cardiovascular-related hospitalization.